Citius Pharmaceuticals Inc (NASDAQ: CTXR) stock jumped 1.16% on Friday to $0.77 against a previous-day closing price of $0.76. With 0.49 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.64 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.7770 whereas the lowest price it dropped to was $0.7630. The 52-week range on CTXR shows that it touched its highest point at $1.71 and its lowest point at $0.60 during that stretch. It currently has a 1-year price target of $8.00. Beta for the stock currently stands at 1.38.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CTXR was up-trending over the past week, with a rise of 0.38%, but this was up by 9.55% over a month. Three-month performance dropped to -14.75% while six-month performance fell -34.50%. The stock lost -29.74% in the past year, while it has lost -2.16% so far this year. A look at the trailing 12-month EPS for CTXR yields -0.21 with Next year EPS estimates of 0.73. For the next quarter, that number is -0.02. This implies an EPS growth rate of 30.43% for this year and 556.25% for next year.
Float and Shares Shorts:
At present, 158.86 million CTXR shares are outstanding with a float of 146.55 million shares on hand for trading. On Oct 30, 2023, short shares totaled 16.89 million, which was 10.63% higher than short shares on Sep 28, 2023. In addition to Mr. Leonard L. Mazur as the firm’s Co-Founder, CEO, Chairman & Secretary, Mr. Myron Z. Holubiak serves as its Co-Founder & Executive Vice Chairman.
Through their ownership of 10.67% of CTXR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 9.80% of CTXR, in contrast to 7.75% held by mutual funds. Shares owned by individuals account for 5.84%. As the largest shareholder in CTXR with 4.51% of the stake, BlackRock Fund Advisors holds 7,167,102 shares worth 7,167,102. A second-largest stockholder of CTXR, The Vanguard Group, Inc., holds 6,710,505 shares, controlling over 4.22% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in CTXR, holding 2,675,375 shares or 1.68% stake. With a 2.60% stake in CTXR, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 4,132,683 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 1.77% of CTXR stock, is the second-largest Mutual Fund holder. It holds 2,808,022 shares valued at 2.11 million. Vanguard Extended Market Index Fu holds 1.21% of the stake in CTXR, owning 1,925,707 shares worth 1.45 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CTXR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CTXR analysts setting a high price target of $8.00 and a low target of $8.00, the average target price over the next 12 months is $8.00. Based on these targets, CTXR could surge 938.96% to reach the target high and rise by 938.96% to reach the target low. Reaching the average price target will result in a growth of 938.96% from current levels.
Summary of Insider Activity:
Insiders traded CTXR stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.